Advanced Portfolio Management LLC Takes $441,000 Position in CVS Health Corporation $CVS

Advanced Portfolio Management LLC purchased a new stake in CVS Health Corporation (NYSE:CVS) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 5,555 shares of the pharmacy operator’s stock, valued at approximately $441,000. CVS Health comprises 1.3% of Advanced Portfolio Management LLC’s portfolio, making the stock its 28th biggest position.

A number of other institutional investors have also made changes to their positions in CVS. Norges Bank bought a new stake in shares of CVS Health in the 4th quarter valued at approximately $1,666,265,000. Wellington Management Group LLP increased its holdings in shares of CVS Health by 391.6% in the 3rd quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock valued at $477,273,000 after acquiring an additional 5,042,816 shares during the last quarter. Amundi grew its stake in CVS Health by 95.3% during the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after buying an additional 3,637,943 shares during the last quarter. Capital Research Global Investors grew its stake in CVS Health by 24.5% during the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after buying an additional 2,253,531 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in CVS Health by 70.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock worth $399,125,000 after buying an additional 2,188,307 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

Insider Buying and Selling at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 3,441,551 shares of company stock valued at $323,703,977. Insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

CVS has been the subject of a number of recent research reports. Piper Sandler restated an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a research note on Monday, June 1st. Wells Fargo & Company upped their price objective on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Argus upped their price objective on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a research note on Thursday, June 11th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of CVS Health in a research note on Friday, May 8th. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $100.68.

CVS Health Trading Down 1.6%

NYSE:CVS opened at $99.06 on Thursday. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $102.77. The stock has a market cap of $126.40 billion, a price-to-earnings ratio of 43.64, a PEG ratio of 0.99 and a beta of 0.62. The business has a fifty day moving average of $88.51 and a 200-day moving average of $81.24. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.